Xeloda Combination Studies Get Combined NCCN/Roche Support
This article was originally published in The Pink Sheet Daily
Executive Summary
Nine National Comprehensive Cancer Network studies are examining the cancer therapy Xeloda in solid tumors.
You may also be interested in...
Xeloda Stomach Cancer Filing Will Likely Reach EU Before FDA, Roche Says
A pivotal trial found Xeloda in combination with cisplatin was non-inferior to the current standard-of-care for advanced gastric cancer, firm says.
Xeloda Stomach Cancer Filing Will Likely Reach EU Before FDA, Roche Says
A pivotal trial found Xeloda in combination with cisplatin was non-inferior to the current standard-of-care for advanced gastric cancer, firm says.
Roche's Xeloda Shows Significant Survival Benefit In Pancreatic Cancer
Combo therapy of Xeloda plus gemcitabine shows median survival of 7.4 months versus six months with Gemzar alone.